Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03955185
Other study ID # RWS cervical cancer
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2019
Est. completion date May 2024

Study information

Verified date September 2019
Source Huazhong University of Science and Technology
Contact Ding Ma, MD;PHD
Phone +86-027-83662681
Email dma@tjh.tjmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cervical cancer is the most common cause of death from gynecological cancer world-wide. With technological innovation, minimally invasive or even non-invasive medical treatment has become a trend. Since the first cases of laparoscopic radical hysterectomy of cervical cancer have been reported in 1992, many single-center observational cohort studies have shown that compared to open abdominal surgery ,minimally invasive surgery (laparoscopic or robotic radical hysterectomy) showed advantages of less blood loss, shorter hospital stay and fewer intraoperative complications, while the 5-year survival and disease-free survival were similar. The NCCN guidelines and ESGO recommendations also clearly indicated that patients with FIGO stage IA2 -IIA cervical cancer could undergo open or laparoscopic/robotic radical hysterectomy. However, in October 2018, the results of two studies published in the《New England Journal of Medicine》have subverted our traditional perception of minimally invasive surgery and caused widespread controversy in the field of gynecologic oncology treatment. Both studies showed that the survival rate in the minimally invasive surgery group was lower than that in the open surgery group.

The results of these two studies have brought unprecedented doubts and challenges to the minimally invasive surgery for cervical cancer. The MD Anderson Cancer Center has even stopped minimally invasive surgery for cervical cancer. Several hospitals in Hong Kong have responded similarly. The NCCN guidelines are also quickly updated based on the results of those studies: patients should be informed of the results of this study and doctors should respect the patient's choices. The above research results have also attracted the attention of many gynecological oncologists in the mainland China. Some experts questioned the design of this study design as well as surgical skills. We need to look at these findings cautiously. So, we launched a real-world study of clinical outcomes affected by different surgical treatment for patients of early stage cervical cancer. We plan to recruit 2000 patients with early cervical cancer from 20-30 selected surgical centers nationwide and perform surgery on patients with qualified and experienced doctors.We will inform the patients current status of the study in detail, divide the patients into different observational group according to their choices on surgical methods. The patients will be followed up closely after surgery. We will compare the differences in clinical outcomes between the two surgical methods and conduct subgroup and stratified analysis. We hope that this study can truly reflect the actual status and clinical l level of early cervical cancer treatment in China, and provide a high level of clinical evidence for the treatment of cervical cancer in China .


Description:

The study is a non-randomized, prospective, multi-center, clinical study.Patients with early cervical cancer who were enrolled will be divided into two groups: minimally invasive surgery group (group A) and open abdominal surgery group (group B) according to the patient's choice on surgical methods.We will standardize the surgery details according to the factors that may affect the prognosis of cancer treatment in the minimally invasive surgery of cervical cancer, such as : emphasizing the tumor-free principle of surgery; using a ligation band to tighten the vagina before cutting the vagina; avoiding the use of the cup-shaped uterine manipulator;reducing frequent changes in CO2 abdominal pressure;or using a laparoscope-assist transvaginal hysterectomy and other methods to avoid the risk of tumor tissue shedding. Patients with high risk factors after surgery will receive follow-up treatment according to the 2018 NCCN guidelines.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date May 2024
Est. primary completion date May 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients with FIGO stage (2018) IA1 (with lymph vascular space invasion), IA2, IB1, IB2 or IIA1 disease

- Preoperative histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix

- Age = 65 years old;

- Physical grading: Karnofsky score = 60 points;

- Initial treatment;

- Voluntarily joined the study, signed informed consent, willing to comply, and cooperative with follow-up; (Note: The maximum diameter of the cervical lesion is subject to MRI measurements)

Exclusion Criteria for Preoperative Patients:

- Patients with contraindications to surgery;

- Patients who have previously received pelvic/abdominal radiation or chemotherapy;Patients who had received radiotherapy and chemotherapy for other cancers in the past.

- Patients with evidence of extra cervical metastases by CT, MRI or PET.

- Unable or unwilling to sign informed consent.

- Unable or unwilling to comply with research requirements.

- Patients with diameter of lymph node metastasis = 2 cm by preoperative MRI.

- Patients with pregnancy.

- Patients requiring fertility-preserving surgery.

- Patients who had previously received subtotal hysterectomy.

- Patients participating in other clinical trials.

- Patients with other reasons not suitable clinical trials identified by researchers.

Exclusion Criteria for Postoperative Patients:

- Postoperative pathology: endometrioid adenocarcinoma, clear cell carcinoma, special type adenocarcinoma, neuroendocrine carcinoma (small cell carcinoma), tuberculosis.

- Postoperative tumor size = 4 cm.

- Patients with abdominal aortic lymph node metastasis.

- Patients with severe postoperative complications that are not suitable for adjuvant therapy and affect patient follow-up.

- Patients who did not follow requirements for various reasons (except for various complications and deaths caused by tumor recurrence and metastasis).

- Situation which researchers believe that treatment should be terminated.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
minimally invasive surgery
Laparoscopic or robotic assisted radical hysterectomy
open abdominal surgery
Traditional open abdominal radical hysterectomy

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Ding Ma

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary disease-free survival (DFS) of 3 years and 5 years DFS was definite as the time from surgery to disease recurrence up to 5 years
Secondary overall survival (OS) of 3 years and 5 years OS was defined as time from surgery to death by any cause up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04114968 - Offering Cervical Cancer Screening to Older Women
Active, not recruiting NCT05682950 - Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 2
Completed NCT05022511 - Three Birds With One Stone N/A
Recruiting NCT06439706 - HPV Self-sampling for Underscreened Latinas N/A
Active, not recruiting NCT05869123 - Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 1/Phase 2
Recruiting NCT03739944 - Different Surgical Approaches in Patients of Early-stage Cervical Cancer Phase 3
Terminated NCT03020121 - Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples N/A
Completed NCT04679675 - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial N/A
Active, not recruiting NCT03994055 - Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer N/A
Recruiting NCT04974424 - Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV
Recruiting NCT03308591 - Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients Phase 3
Active, not recruiting NCT05880485 - Online Adaptive Radiotherapy Cervical Cancer With Reduced Margin for Cervical Cancer Phase 1/Phase 2
Terminated NCT03100409 - Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients N/A
Not yet recruiting NCT03971032 - An In-vitro Real-time System Based on Tissue Smears to Identify Malignancy During Hysteroscopic Procedure N/A
Recruiting NCT04516616 - Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Phase 2
Recruiting NCT04061967 - SMS-based Summons in Cervical Screening N/A
Completed NCT03122275 - Stepwise Strategy to Improve CANcer Screening Adherence: Cervical Cancer N/A